Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden
AbstractAims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA). Secondary to investigate the current diagnostic trajectory for patients...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2023.2292686 |
| _version_ | 1797302140534784000 |
|---|---|
| author | Frida Hjalte Jenny M. Norlin Linda Alverbäck-Labberton Katarina Johansson Gerhard Wikström Per Eldhagen |
| author_facet | Frida Hjalte Jenny M. Norlin Linda Alverbäck-Labberton Katarina Johansson Gerhard Wikström Per Eldhagen |
| author_sort | Frida Hjalte |
| collection | DOAJ |
| description | AbstractAims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA). Secondary to investigate the current diagnostic trajectory for patients with ATTR-CM in Sweden.Methods A stratified inclusion of patients with a confirmed diagnosis of ATTR-CM in different NYHA classes. Data was extracted from medical records in two cardiology clinics in Sweden. Healthcare resource use data were retrospectively collected for 12 months.Results 38 patients were included, of whom 7 were in NYHA class II, 20 in class III and 4 in class IV. The total cost of health care per patient increased from SEK 69,000 (€6800) in NYHA stage II, SEK 219,000 (€21,500) in NYHA stage III, to SEK 638,000 (€62,900) in stage IV, mainly due to an increase in inpatient stays. Mean time (standard deviation, SD) from any cardiac related diagnosis prior to ATTR-CM diagnosis was 3.5 (3.1) years.Conclusions Advanced ATTR-CM stages are associated with significant healthcare costs, as patients more often require resource-intensive inpatient care. The current diagnostic trajectory of ATTR-CM in this study was characterized by a diagnostic delay of several years. |
| first_indexed | 2024-03-07T23:32:30Z |
| format | Article |
| id | doaj.art-53b25cafcea249289d53af381e026c49 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-07T23:32:30Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-53b25cafcea249289d53af381e026c492024-02-20T11:58:25ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155210.1080/07853890.2023.2292686Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in SwedenFrida Hjalte0Jenny M. Norlin1Linda Alverbäck-Labberton2Katarina Johansson3Gerhard Wikström4Per Eldhagen5The Swedish Institute for Health Economics, Lund, SwedenThe Swedish Institute for Health Economics, Lund, SwedenPfizer AB, Stockholm, SwedenPfizer AB, Stockholm, SwedenDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, SwedenDepartment of Medicine Karolinska Institutet and Department of Cardiology, Karolinska University Hospital, Stockholm, SwedenAbstractAims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA). Secondary to investigate the current diagnostic trajectory for patients with ATTR-CM in Sweden.Methods A stratified inclusion of patients with a confirmed diagnosis of ATTR-CM in different NYHA classes. Data was extracted from medical records in two cardiology clinics in Sweden. Healthcare resource use data were retrospectively collected for 12 months.Results 38 patients were included, of whom 7 were in NYHA class II, 20 in class III and 4 in class IV. The total cost of health care per patient increased from SEK 69,000 (€6800) in NYHA stage II, SEK 219,000 (€21,500) in NYHA stage III, to SEK 638,000 (€62,900) in stage IV, mainly due to an increase in inpatient stays. Mean time (standard deviation, SD) from any cardiac related diagnosis prior to ATTR-CM diagnosis was 3.5 (3.1) years.Conclusions Advanced ATTR-CM stages are associated with significant healthcare costs, as patients more often require resource-intensive inpatient care. The current diagnostic trajectory of ATTR-CM in this study was characterized by a diagnostic delay of several years.https://www.tandfonline.com/doi/10.1080/07853890.2023.2292686ATTR-CMcostsdiagnosishealth care resourcesNYHA |
| spellingShingle | Frida Hjalte Jenny M. Norlin Linda Alverbäck-Labberton Katarina Johansson Gerhard Wikström Per Eldhagen Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden Annals of Medicine ATTR-CM costs diagnosis health care resources NYHA |
| title | Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden |
| title_full | Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden |
| title_fullStr | Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden |
| title_full_unstemmed | Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden |
| title_short | Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden |
| title_sort | health care resource use diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in sweden |
| topic | ATTR-CM costs diagnosis health care resources NYHA |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2023.2292686 |
| work_keys_str_mv | AT fridahjalte healthcareresourceusediagnosticdelayanddiseaseburdenintransthyretinamyloidcardiomyopathyinsweden AT jennymnorlin healthcareresourceusediagnosticdelayanddiseaseburdenintransthyretinamyloidcardiomyopathyinsweden AT lindaalverbacklabberton healthcareresourceusediagnosticdelayanddiseaseburdenintransthyretinamyloidcardiomyopathyinsweden AT katarinajohansson healthcareresourceusediagnosticdelayanddiseaseburdenintransthyretinamyloidcardiomyopathyinsweden AT gerhardwikstrom healthcareresourceusediagnosticdelayanddiseaseburdenintransthyretinamyloidcardiomyopathyinsweden AT pereldhagen healthcareresourceusediagnosticdelayanddiseaseburdenintransthyretinamyloidcardiomyopathyinsweden |